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Objectives: With the prevalence of obesity in the United States, a signiﬁcant proportion of robot-assisted
laparoscopic prostatectomy (RALP) candidates have an elevated body mass index (BMI). We determine if
this impacts on the clinical outcomes of RALP.Methods: 218 consecutive patients underwent RALP were
identiﬁed from a prospectively maintained RALP database recorded and compared for their de-
mographics, clinical outcomes and adverse events in normal weight (BMI <25 kg/m2), overweight (BMI
25 and <30 kg/m2) and obese (BMI 30 kg/m2) groups. Results: 36 normal weight, 115 overweight and
67 obese patients were identiﬁed. There were no signiﬁcant differences in demographic data among the
three groups except for mean BMI (23.1 vs. 27.5 vs. 32.8 kg/m2, p < 0.001). The median operative time
was longer in obese patients compared to both overweight (210 vs. 189 min, p ¼ 0.031) and normal
weight (210 vs. 177 min, p ¼ 0.008) patients. There were no signiﬁcant differences in median estimated
blood loss, mean prostate volume, positive surgical margin rate and time to continence without pads. The
median urethral catheter duration and hospitalization were similar in all groups. Patients with elevated
BMI had a signiﬁcantly higher median Gleason score (p ¼ 0.046) and incidence of pathologic T3 disease
(p ¼ 0.038). The incidence of adverse events was low and there were no signiﬁcant differences among
the three groups (p > 0.05).Conclusions: Elevated BMI appears to increase the RALP operative time, but
has little impact on other intraoperative parameters, clinical outcomes or patient morbidity. RALP is a
safe and effective procedure in patients with elevated BMI.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.vasive and Robotic Surgery,
H, USA.
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The prevalence of obesity has substantially increased in almost
all countries. Currently, approximately one-third of adults in the
United State are obese [1]. Obesity has been linked to several
cancers and body mass index (BMI: weight in kilograms/height in
squaremeters) as a surrogate of adiposity has been evaluated for its.
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prostate cancer-speciﬁc mortality [2]. The incidence of PCa has
increased steadily and is the second most lethal malignancy in men
in the United States, where a man has a 12.5% chance of suffering
PCa and a greater than 70% likelihood of being overweight (BMI
25 and <30 kg/m2) or obese (BMI 30 kg/m2) [3]. Urologists have
to increasingly confront PCa patients with an elevated BMI, posing
challenges for its surgical treatment.
Robot-assisted laparoscopic prostatectomy (RALP) is gaining
popularity as a surgical option for the treatment of clinically
localized PCa. With experience, the selection criteria for this pro-
cedure have broadened. There have been several reports on how
obesity inﬂuenced the clinical outcomes following RALP using the
“standard” da Vinci robotic system (Intuitive Surgical, Inc, Sunny-
vale, CA) [4e8]. The da Vinci Si system has been reported to allow
for shorter procedure compared to the “standard” da Vinci system
[9]. In this study, we evaluate our experience with RALP using the
da Vinci Si system in overweight and obese patients, compared
with a normal weight cohort.
2. Methods
2.1. Patient enrollment and preoperative evaluation
Approval for this study was granted by the Institutional Review
Board at the University of Oklahoma Health Sciences Center. Pro-
spectively collected data from the records of consecutive patients
diagnosed with clinically localized PCa who underwent RALP by a
single surgeon (CW) between March 2009 and March 2011 were
reviewed. Based on the clinical deﬁnitions for overweight and
obesity [10], patients were stratiﬁed into three groups: normal
weight (BMI<25 kg/m2), overweight (BMI 25 and <30 kg/m2) and
obese (BMI30 kg/m2). Surgical indications were in accordance
with the PCa management guidelines of the American Urological
Association, Inc [11].
All patients underwent preoperative evaluation, including
complete medical history, age, weight, height, digital rectal exam-
ination, American Society of Anesthesiologists (ASA) risk score,
American Urological Association Symptom Score (AUASS), Quality
of Life (QoL) score, Sexual Health Inventory for Men (SHIM), serum
prostate-speciﬁc antigen (PSA), transrectal ultrasonography (TRUS)
measurements of prostate volume, and employment of computer-
ized tomography and nuclear bone scan if clinically indicated. All
patients were diagnosed with PCa by TRUS-guided prostate bi-
opsies at a minimum 6 weeks prior to surgery. Patients with PCa of
clinical stage T2 without evidence of metastasis were considered
candidates for RALP.
2.2. Surgical technique
RALP was performed in a six-port transperitoneal approach
with a four-armed da Vinci Si robotic system. In brief, laparoscopic
lysis of adhesions was performed initially if required. Using an
anterior approach, a bladder neck sparing procedure was prefer-
entially performed for all patients. Based on the volume of disease
on the TRUS biopsy specimen, bilateral or unilateral neurovascular
bundles were spared when appropriate using an interfascial sharp
dissection technique without the use of mono or bipolar electro-
cautery. Bladder neck reconstruction was performed when
required. Pelvic lymph node dissection (PLND) was performed in
patients who had a serum PSA >10 ng/mL or a primary Gleason
score >7. A modiﬁed one layer van-Velthoven vesicourethral
anastomosis technique [12] was performed using a running
double-armed 3-0 Monocryl suture containing two RB1 needles.
The integrity of the anastomosis was routinely checked by bladderirrigationwith normal saline. A JacksonePratt (JP) drainwas placed
in the pelvis.
2.3. Postoperative care and evaluation
Routine postoperative care was administered including oral
analgesia and antibiotics. The JP drain was removed on post-
operative day 1 unless high drain output with an elevated ﬂuid
creatininewas conﬁrmed. Patients were routinely discharged home
on postoperative day 1 with a urethral catheter in place and
returned to our clinic on postoperative day 5 or 6 (clinic logistics)
for a cystogram prior to discontinuation of the catheter. Penile
rehabilitation [phosphodiesterase-5 (PDE-5) inhibitor and vacuum
erection device (VED)] was offered to all patients with preoperative
erectile function.
Patients were followed at 6 weeks, 3 months, and subsequently
every 3 months for the ﬁrst 2 years and then every 6 months.
AUASS, QoL, SHIM, Pad usage, potency, serum PSA value and
adverse events were recorded at each visit. Continence was deﬁned
as no urine leakage and wearing no pads.
2.4. Statistical analysis
Continuous variables were presented as mean ± standard de-
viation (SD) or median if not in a normal distribution, while cate-
gorical variables were presented as a percentage. Statistical analysis
was performed using GraphPad InStat, version 3.0 (GraphPad
Software, San Diego, CA). Comparison of continuous variables with
normal distribution were completed with t-test or Analysis of
Variance (ANOVA), otherwise, Wilcoxon or KruskaleWallis test was
used. Paired tests were completed with paired t-test or Wilcoxon
sign rank-sum test, depending on the normality of the data. A chi-
square or Fisher's exact test was used for statistical comparison of
categorical variables. A two-sided p < 0.05 was considered statis-
tically signiﬁcant.
3. Results
Baseline demographic information for the 218 patient cohort is
presented in Table 1. There were 36 (16.5%) normal weight, 115
(53.8%) overweight and 67 (30.7%) obese patients with signiﬁcant
differences in mean BMI (p < 0.001). Overall, patients in the
different BMI categories had similar demographic parameters.
Mean ASA and prostate TRUS volume trended toward an increment
with increasing BMI without reaching statistical signiﬁcance
(p¼ 0.083 and p¼ 0.774). Approximately 94% of patients presented
with clinical T1c disease in each group and there was no difference
in the median biopsy Gleason score between the groups
(p ¼ 0.488). Mean age, preoperative serum PSA level, AUASS, QoL
and SHIM were similar among all groups.
Operative time for RALP tended to prolong with increasing BMI
(p ¼ 0.020); signiﬁcant differences in median operative time was
noted between normal weight and obese men (177 vs. 210 min,
p ¼ 0.008) and between overweight and obese men (189 vs.
210 min, p ¼ 0.031), while the difference between normal weight
and overweight groups (177 vs. 189 min, p ¼ 0.339) did not reach
statistical signiﬁcance. Patients in the three groups had an equiv-
alent median estimated blood loss of 75 mL (p ¼ 0.315). Patients
with elevated BMI did not require more intravenous ﬂuids intra-
operatively (p ¼ 0.069). No patients required conversion to open
surgery or intraoperative blood transfusion (Table 2).
Overall, the mean follow-up was 24.8 ± 11.5 months (18e42
months). The pathologic features and postoperative data are sum-
marized in Table 3. Obese patients had a signiﬁcantly higher pre-
operative median Gleason score (7 vs. 6, p ¼ 0.046). The median
Table 1
Patient demographics and tumor characteristics.
Parameter Normal Overweight Obese p-value
Age (years), mean ± SD (range) 61.8 ± 5.5 (49.1e72.0) 63.1 ± 6.9 (45.3e78.1) 62.7 ± 6.5 (47.0e75.1) 0.594
BMI (kg/m2), mean ± SD (range) 23.1 ± 1.5 (19.8e24.8) 27.5 ± 1.5 (25.0e29.8) 32.8 ± 2.6 (30.1e43.0) <0.001
ASA, mean ± SD (range) 2.1 ± 0.4 (1e3) 2.2 ± 0.5 (1e3) 2.3 ± 0.5 (2e3) 0.083
PSA (ng/mL), mean ± SD (range) 6.1 ± 3.4 (0.6e15.7) 6.7 ± 5.4 (0.6e37.0) 5.5 ± 3.6 (0.5e20.8) 0.288
Prostate TRUS volume (mL), mean ± SD (range) 41.2 ± 13.5 (17.3e79.8) 42.6 ± 12.4 (15.6e75.0) 43.7 ± 15.5 (19.0e96.3) 0.774
AUASS, mean ± SD (range) 10.9 ± 6.6 (0e34) 10.0 ± 7.6 (0e33) 8.6 ± 6.9 (0e31) 0.163
QoL, mean ± SD (range) 1.7 ± 1.2 (0e5) 2.0 ± 1.5 (0e8) 1.8 ± 1.4 (0e6) 0.744
SHIM, mean ± SD (range) 16.5 ± 7.8 (1e25) 16.1 ± 7.9 (0e25) 16.2 ± 8.3 (1e25) 0.937
PCa family history, n (%) 6 (16.7) 19 (16.5) 12 (17.9) 0.547
Clinical stage, n (%)
T1c 34 (94.4) 108 (93.9) 63 (94.0) 0.993
T2 2 (5.6) 7 (6.1) 4 (6.0) 0.993
Gleason score (biopsy), median (range) 6.0 (6e9) 6.0 (6e9) 6.0 (4e9) 0.488
Gleason score (biopsy), n (%)
5 0 (0) 0 (0) 2 (3.0) 0.103
6 24 (66.7) 77 (67.0) 36 (52.2) 0.179
7 10 (27.8) 30 (26.1) 23 (34.3) 0.067
S8 2 (5.6) 8 (7.0) 6 (9.0) 0.580
P-value in bold when it was lower than 0.05 and considered statistically signiﬁcant.
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preoperative biopsy values in all groups. Compared with 5.6%
normal weight patients having pT3 disease, there was a signiﬁ-
cantly higher incidence of pT3 disease in the overweight (5.6% vs.
21.7%, p¼ 0.038) and obese (5.6% vs. 11.9%, p¼ 0.026) groups, while
no difference was noted between overweight and obese patients
(21.7% vs. 11.9%, p ¼ 1.821). Overweight and obese patients were
also more likely to have a higher rate of positive margins (18.3% and
13.4%) compared to normal weight patients (8.3%); however, this
trend did not reach statistical signiﬁcance (p ¼ 0.313). Pathologic
prostate volume did not statistically differ among the groups
(p ¼ 0.861), but was remarkably elevated in the normal weight
(p ¼ 0.028) and obese (p < 0.001) groups compared to their pre-
operative prostate TRUS volume. There were no signiﬁcant differ-
ences in median hospitalization (p ¼ 0.425), JP drain duration
(p ¼ 0.596) and urethral catheter duration (p ¼ 0.582) among the
groups. At six weeks follow-up, AUASS and QoL were similar among
the groups with signiﬁcant improvement from the baseline values
prior to RALP (Table 4). There were comparable early urinary
continence (no pad usage) rates among the groups (p ¼ 0.829) and
almost all patients in each group were continent 12 months after
surgery, having similar median times (8.0 vs. 8.0 vs. 9.0 weeks) to
achieve continence (p ¼ 0.992). The potency rates at 12 months
were not signiﬁcantly different (p ¼ 0.504). The percentages of
patients having undetectable serum PSA level (<0.2 ng/mL) within
12 months were similar among the groups (p ¼ 0.327).
The overall incidence of postoperative adverse events in the
three groupswere not signiﬁcantly different (p¼ 0.879). Two (1.7%)
overweight patients and one (1.5%) obese patient required blood
transfusion due to anemia (hemoglobin <12 g/dL) secondary toTable 2
Intraoperative parameters.
Parameters Normal
Operative time (min), median (range) 177 (120e290)
Estimated blood loss (mL), median (range) 75 (50e125)
Intravenous ﬂuids (mL), median (range) 1850 (1000e3000)
Nerve sparing, n (%)
Bilateral þ Unilateral 35 (97.2)
Non 1 (2.8)
Lysis of adhesions, n (%) 2 (5.6)
Bladder neck reconstruction, n (%) 0 (0)
Bilateral pelvic lymph node dissection, n (%) 2 (5.5)
P-value in bold when it was lower than 0.05 and considered statistically signiﬁcant.acute blood loss in the ﬁrst 24 h after surgery, none of whom
required surgical intervention. Comparable rates of patients had a
prolonged urine leak (>5e6 days) among the three groups
(p ¼ 0.357), which was successfully resolved by extension of the
catheterization interval. One (1.5%) fascial dehiscence and one
(0.9%) port site hernia were noted in the obese and overweight
group, respectively. One (0.9%) overweight and one (1.5%) obese
patient experienced deep vein thrombosis. One (2.8%) normal
weight, two (1.7%) overweight and two (3.0%) obese patients
developed bladder neck contractures (p ¼ 0.844). (Table 3).
4. Discussion
The prevalence of both obesity and PCa often confronts the
urologist with obese patients having PCa. Radical retropubic pros-
tatectomy has been reported to be more technically challenging in
obese patients, even to the experienced surgeon, due to difﬁculties
in perineal exposure and unfavorable visualization [13,14]. Perineal
prostatectomy and laparoscopic radical prostatectomy have been
proposed as preferable techniques for such patients [15,16]. How-
ever, these approaches have a steep learning curve and have yet to
be universally accepted due to their technically demanding nature.
Consequently, it may be recommended for some obese men with
PCa to lose weight for surgery or be treated with radiation therapy.
RALP has become an accepted option of prostate cancer therapy
with more than 65% of radical prostatectomies being robot-assisted
in the United State [9]. Most, but not all studies relating obesity and
RALP with the da Vinci standard system have demonstrated
favorable clinical outcomes [4e8]. The impact of obesity on the
clinical outcomes following RALP with the da Vinci Si system hasOverweight Obese p-value
189 (120e360) 210 (120e400) 0.020
75 (17e250) 75 (50e250) 0.315
1750 (800e4000) 1500 (1000e3000) 0.690
105 (91.3) 63 (94.0) 0.444
10 (8.7) 4 (6.0) 0.444
3 (2.6) 2 (3.0) 0.676
2 (1.7) 0 (0) 0.405
8 (7.0) 6 (9.0) 0.798
Table 3
Pathologic and postoperative data.
Clinical outcomes Normal Overweight Obese p-value
Follow-up (months), mean ± SD (range) 21.3 ± 9.7 (1.5e36) 19.6 ± 0.6 (0.3e36) 23.8 ± 13.5 (0.3e36) 0.130
Pathologic stage, n (%)
pTx 1 (2.8) 0 (0) 0 (0) 0.079
pT2a 6 (16.7) 18 (15.7) 9 (13.4) 0.887
pT2b 0 (0) 2 (1.7) 2 (3.0) 0.557
pT2c 27 (75.0) 70 (60.7) 48 (71.6) 0.165
pT3 2 (5.6) 25 (21.7) 8 (11.9) 0.038
Gleason score (surgery), median (range) 6.0 (5e9) 6.0 (5e9) 7.0 (6e9) 0.046
Gleason score (surgery), n (%)
5 2 (5.6) 1 (0.9) 0 (0) 0.056
6 24 (66.7) 71 (61.7) 35 (52.2) 0.290
7 7 (19.4) 38 (33.0) 27 (40.3) 0.100
S8 3 (8.3) 5 (4.3) 5 (7.5) 0.559
Gleason upgraded, a n (%) 3/36 (8.3) 15/115 (13.0) 7/67 (10.4) 0.698
Gleason downgraded,b n (%) 2/36 (5.6) 1/115 (0.9) 0/67 (0) 0.055
Positive margins, n (%) 3 (8.3) 21 (18.3) 9 (13.4) 0.313
Pathologic prostate volume (mL), mean ± SD (range) 44.3 ± 12.2 (12e68) 45.6 ± 13.6 (15e85) 44.4 ± 14.8 (21e82) 0.816
JP drain duration (days), median (range) 1.0 (1e6) 1.0 (1e6) 1.0 (1e3) 0.596
Hospitalization (days), median (range) 1.0 (1e13) 1.0 (1e3) 1.0 (1e5) 0.425
Urethral catheter duration (days), median (range) 5.0 (5e23) 6.0 (3e34) 5.0 (4e26) 0.582
Urethral catheter duration, n (%)
5 days 19 (52.7) 59 (51.3) 42 (62.7) 0.316
7 days 32 (88.9) 103 (89.6) 60 (89.6) 0.993
14 days 35 (97.2) 113 (98.3) 64 (95.6) 0.553
Urinary retention after catheter removal, n (%) 2 (5.6) 3 (2.6) 2 (3.0) 0.676
AUASS at 6 weeks, mean ± SD (range) 5.7 ± 2.5 (2e15) 5.6 ± 3.0 (0e20) 6.0 ± 2.6 (1e12) 0.666
QoL at 6 weeks, mean ± SD (range) 1.5 ± 1.0 (0e4) 1.3 ± 1.1 (0e5) 1.4 ± 1.0 (0e3) 0.596
Pad use per day at 6 weeks, median (range) 1.0 (0e9) 1.0 (0e5) 1.0 (0e7) 0.883
Urinary continence, n (%)
3 months 26/36 (72.2) 77/114 (67.5) 46/65 (70.8) 0.829
12 months 30/32 (93.8) 94/98 (95.9) 59/63 (93.7) 0.783
Time to continence (weeks), median (range) 8.0 (0.7e36) 8.0 (1e36) 9.0 (0.7e36) 0.992
Potency at 12 months, n (%) 13/22 (59.1) 27/53 (50.9) 15/25 (60.0) 0.504
Undetectable PSAc at 12 months, n (%) 22/23 (95.7) 62/66 (93.9) 36/36 (100.0) 0.327
Adverse events, n (%) 4 (11.1) 10 (8.7) 7 (10.4) 0.879
Blood transfusion 0 (0) 2 (1.7) 1 (1.5) 0.733
Prolonged urine leak 2 (5.6) 2 (1.7) 1 (1.5) 0.357
Fascial dehiscence 0 (0) 0 (0) 1 (1.5) 0.322
Port site hernia 0 (0) 1 (0.9) 0 (0) 0.638
Pelvic hematoma 1 (2.8) 1 (0.9) 1 (1.5) 0.689
Urinary tract infection 0 (0) 1 (0.9) 0 (0) 0.638
Deep vein thrombosis 0 (0) 1 (0.9) 1 (1.5) 0.748
Bladder neck contractures 1 (2.8) 2 (1.7) 2 (3.0) 0.844
P-value in bold when it was lower than 0.05 and considered statistically signiﬁcant.
a Change from biopsy Gleason score 6 to surgery Gleason score >6.
b Change from biopsy Gleason score S6 to surgery Gleason score <6.
c PSA <0.2 ng/mL.
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BMI (25 kg/m2) resulted in technical difﬁculties or inﬂuenced the
clinical outcomes of RALP using the da Vinci Si system.
Obese patients have higher rates of co-morbid diseases
including, but not limited to diabetes mellitus, hypertension and
coronary artery disease. In our cohort, menwith higher BMI tended
to have an elevated ASA, but this did not reach statistical signiﬁ-
cance (p ¼ 0.083). Likewise, obese patients were noted to have
larger prostates (p¼ 0.774) and lower serum PSA levels (p¼ 0.288).
These ﬁndings were consistent with the results reported by Kopp
et al. that obese menwith PCa have larger prostates than non-obese
men with PCa [17]. The decrease of serum PSA concentrations in
obese patients may be a result of a larger volume of distribution
[18]. However, Christopher et al. suggested that the predictive
ability of the PSA level for tumor volume is not affected by BMI [19].
In contrast to the results that obese patients had signiﬁcantly
poorer baseline SHIM scores and voiding parameters [8], we did not
note any signiﬁcant differences in AUASS, QoL and SHIM among the
three groups. The preoperative Gleason score and clinical stages
were evenly distributed among our study groups, while Hermanet al. reported that obese patients had a higher percentage of
clinical T1c cancers compared with overweight and normal BMI
patients. However, they did not ﬁnd a signiﬁcant difference in
postoperative pathologic stage between these groups [20].
Most RALP studies have reported longer operative times and
greater blood loss in obese patients [5e8]. Our study corroborated
that median operative times were signiﬁcantly higher in obese
compared to overweight and normal weight patients (210 vs. 189
vs. 177 min, p ¼ 0.020). Excessive intraperitoneal and pelvic fatty
tissue may compromise the pelvic space and hinder the surgeon's
visualization, increasing the time required for the surgical dissec-
tion. Longer trocars and adjustment of port placement may help to
minimize these issues. The median operative time (210 min) in
obese patients in our study was shorter than 304 min, 300.6 min
and 353.3 min reported by others [5,6,20]. Shah et al. compared the
intraoperative outcomes of RALP between the two succeeding
generations of the da Vinci surgical platform (da Vinci S robot vs.
ﬁrst-generation standard robot) and found that the da Vinci S robot
allowed for shorter procedure times [9]. Using the da Vinci Si ro-
botic system, we did not ﬁnd statistically signiﬁcant difference in
Table 4
Parameters compared pre- and post-surgery.
Parameter Normal Overweight Obese p-value
AUASS, mean ± SD (range)
Pre-operative 10.9 ± 6.6 (0e34) 10.0 ± 7.6 (0e33) 8.6 ± 6.9 (0e31) 0.163
Post-operative week 6 5.7 ± 2.5 (2e15) 5.7 ± 3.0 (0e20) 6.1 ± 2.6 (1e12) 0.457
p-value <0.001 <0.001 0.027
QoL, mean ± SD (range)
Pre-operative 1.7 ± 1.2 (0e5) 2.0 ± 1.5 (0e8) 1.8 ± 1.4 (0e6) 0.744
Post-operative week 6 1.4 ± 1.0 (0e4) 1.3 ± 1.1 (0e5) 1.5 ± 1.0 (0e3) 0.477
p-value 0.252 <0.001 0.152
Hemoglobin (g/dL), mean ± SD (range)
Pre-operative 14.8 ± 0.8 (13.0e16.0) 14.5 ± 1.2 (10.3e17.0) 15.1 ± 1.2 (12.5e16.3) 0.440
Post-operative day 1 13.0 ± 1.6 (9.9e15.6) 12.1 ± 1.8 (8e15.6) 12.4 ± 1.1 (10.7e15.0) 0.303
p-value <0.001 <0.001 <0.001
Hematocrit (L/L), mean ± SD (range)
Pre-operative 41.7 ± 3.7 (33.7e47.0) 42.9 ± 2.7 (38.1e49.4) 44.1 ± 4.1 (37.0e49.0) 0.035
Post-operative day 1 36.8 ± 5.2 (28.4e44.0) 36.1 ± 4.4 (27.0e44.0) 36.8 ± 4.0 (30.8e46.0) 0.886
p-value 0.031 <0.001 <0.001
Prostate volume (mL), mean ± SD (range)
TRUS volume 41.2 ± 13.5 (17.3e79.8) 42.6 ± 12.4 (15.6e75) 43.1 ± 15.5 (19.0e96.3) 0.774
Pathologic volume 44.3 ± 12.2 (21.0e68.0) 45.6 ± 13.6 (15.0e85.0) 44.4 ± 14.8 (21.0e82.0) 0.816
p-value 0.028 <0.001 0.671
Gleason score, median (range)
Pre-operative 6.0 (6e9) 6.0 (6e9) 6.0 (4e9) 0.488
Post-operative 6.0 (5e9) 6.0 (5e9) 7.0 (6e9) 0.046
p-value 0.622 0.767 0.159
P-value in bold when it was lower than 0.05 and considered statistically signiﬁcant.
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gesting obese patients do not have an increased risk of blood loss
during RALP. No blood transfusion or open surgery conversion was
required. Two (1.7%) overweight patients did not undergo a bladder
neck sparing procedure and required bladder neck reconstruction
due to the presence of a large intravesical median prostate lobe.
Although a similar percentage of patients had an upgraded or
downgraded Gleason score in the three groups, no signiﬁcant
changes in themedian Gleason score were noted after surgery in all
groups. Our data showed that more patients with elevated BMI
tended to have pT3 disease (p ¼ 0.038) and obese patients had a
signiﬁcantly higher median Gleason score (p ¼ 0.046) compared to
overweight and normal weight patients. This suggests that obesity
may be associated with biologically more aggressive PCa. However,
therewere no differences in biochemical recurrence rates at the one
year follow-up interval between the three groups (p¼ 0.327). There
have been mixed reports about surgical margins in obese patients
[6,21]. Although not reaching statistical signiﬁcance in our cohort,
the overweight (18.3%) and obese (13.4%) men had increased posi-
tivemargin rates compared to that of normalweight patients (8.3%).
Our results may reﬂect the aggressive features of the malignancy or
inherent technical challenges of operating on heavy men.
More than half of our patients had their urethral catheter
removed within 5 days post surgery with a low and similar inci-
dence of urinary retention in all groups. Patients with a BMI
25 kg/m2 have been found to have a signiﬁcantly longer duration
of postoperative incontinence both in radical retropubic prosta-
tectomy and RALP cohorts [8,22]. In contrast, we did not identify
signiﬁcant differences in median time to continence and conti-
nence rates at 3 and 12 months follow-up in our three patient
groups. Routine preoperative Kegel exercises and a bladder neck
sparing technique combined with a modiﬁed one layer van-
Velthoven vesicourethral anastomosis that we employ may help
to facilitate the recovery of urinary continence. Limited studies
have reported on the voiding parameters of obese patients. Ahler-
ing et al. noted that obesemen had poorer baseline urinary function
and a higher urinary bother score 3 and 9 months after RALP [8]. In
our cohort, obese patients did not start with more severe voidingsymptoms, and patients in each group showed signiﬁcant AUASS
and QoL improvement at 6 weeks follow-up without a signiﬁcant
difference between the three groups. The discrepancy of results
between studies may be associated with dividing men into two
categories (non-obese and obese) instead of three categories
(normal weight, overweight and obese).
The overall postoperative adverse events experienced by pa-
tients in the different BMI categorieswere similar. Twopatientswith
elevated BMI had deep venous thrombosis which was successfully
resolved without long-term sequelae. Obese patients have been
reported to have increasedplasmaviscosityandblood viscosity [23].
Twopatientswith elevatedBMI required blood transfusion for acute
anemia without requiring surgical intervention. The incidence of
bladder neck contracturewas low and comparable among the three
groups, and all were successfully managed by transurethral incision
of the bladder neck contracture (TUIBNC) with the holmium laser.
Obese patients had a signiﬁcantly elevated serum hematocrit level
but similar hemoglobin level preoperatively, compared to normal
weight (p ¼ 0.035) and overweight (p ¼ 0.440) patients. Serum
hemoglobin and hematocrit levels, although clinically not apparent,
were signiﬁcantly decreased postoperatively, but no remarkable
differences were noted between the groups in our cohort. This was
consistent with the results reported by Brown et al. where a similar
hemoglobin decrease was found in non-obese and obese patients
after laparoscopic radical prostatectomy [16]. Hemodilution sec-
ondary to intravenous ﬂuid resuscitation may be more likely than
intraoperative blood loss to account for the decrease of hemoglobin
and hematocrit. Our paired statistical analysis showed that patho-
logic prostate volumes were higher than the preoperative TRUS
volumes, echoing the results reported by Sajadi et al. that TRUS
volume underestimated specimen weight and there was no signif-
icant effect of BMI on TRUS volume accuracy [24].
One of the limitations of our prospective study is the pending
follow-up of patients, resulting in only part of the cohort reaching
each follow-up interval. Factors that may have contributed to this
include the insufﬁcient time interval post surgery and the
geographic distribution of our patients, limiting follow-up
compliance.
X. Gu et al. / International Journal of Surgery 12 (2014) 1055e106010605. Conclusions
BMI did not signiﬁcantly affect the clinical outcomes of RALP for
the treatment of clinically localized PCa. Despite being technically
sophisticated, RALP is a safe and effective procedure in patients
with elevated BMI.
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